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The oncoprotein transcription factor MYC is overexpressed in the
majority of cancers. Key to its oncogenic activity is the ability of
MYC to regulate gene expression patterns that drive and maintain
the malignant state. MYC is also considered a validated anticancer
target, but efforts to pharmacologically inhibit MYC have failed.
The dependence of MYC on cofactors creates opportunities for
therapeutic intervention, but for any cofactor this requires struc-
tural understanding of how the cofactor interacts with MYC,
knowledge of the role it plays in MYC function, and demonstration
that disrupting the cofactor interaction will cause existing cancers
to regress. One cofactor for which structural information is avail-
able is WDR5, which interacts with MYC to facilitate its recruit-
ment to chromatin. To explore whether disruption of the MYC–
WDR5 interaction could potentially become a viable anticancer
strategy, we developed a Burkitt’s lymphoma system that allows
replacement of wild-type MYC for mutants that are defective for
WDR5 binding or all known nuclear MYC functions. Using this
system, we show that WDR5 recruits MYC to chromatin to control
the expression of genes linked to biomass accumulation. We fur-
ther show that disrupting the MYC–WDR5 interaction within the
context of an existing cancer promotes rapid and comprehensive
tumor regression in vivo. These observations connect WDR5 to a
core tumorigenic function of MYC and establish that, if a thera-
peutic window can be established, MYC–WDR5 inhibitors could be
developed as anticancer agents.
cancer | chromatin | MYC | lymphoma | cancer therapy
The MYC oncogenes encode a set of 3 highly related proteinsthat feature prominently in cancer. Overexpression of at least
one MYC protein is observed in more than half of all malignan-
cies, and estimates suggest that up to one-third of all cancer deaths
can be attributed to inappropriate MYC expression or activity (1).
MYC proteins function by regulating gene expression, dimerizing
with their obligate partner MAX (2) to form a DNA-binding
transcription factor that controls the transcription of genes
linked to protein synthesis, metabolism, proliferation, and genome
instability—a near perfect suite of activities for the initiation,
progression, and maintenance of the tumorigenic state (1).
The pervasive involvement of MYC in cancer has fueled interest
in the notion that MYC can be targeted to treat malignancies. It is
clear that inhibiting MYC in the context of an existing cancer
promotes tumor regression in mice (3), even in cases where MYC
is not the primary oncogenic lesion (4). A number of strategies
have been developed to mitigate MYC overexpression (5) or to
interfere with cellular processes hijacked by MYC (6), but in terms
of blocking MYC function, the options are limited. Indeed, the
most obvious route to MYC inhibition—disrupting target gene
binding—is daunting, as the MYC:MAX interface is not readily
amenable to pharmacological inhibition. Recently, however, it
emerged that target gene recognition by MYC does not solely
depend on interaction with MAX. Modeling reveals that ∼90%
of MYC binding events in cells cannot be accounted for in terms
of the affinity of MYC:MAX dimers for DNA (7), and a number of
nuclear proteins have been shown to facilitate the recruitment of
MYC to its target genes in the context of chromatin (8–11). If
these chromatin cofactors can be understood, they could expose
new avenues through which the ability of MYC to regulate tu-
morigenic transcriptional programs can be inhibited.
We identified WDR5, a protein that nucleates the assembly of
histone modifier complexes (12), as a factor that facilitates the
recruitment of MYC to chromatin (8). MYC binds directly to a
shallow hydrophobic cleft on WDR5 that encompasses less than
800 Å2 of buried protein surface. Structure-guided mutations in
MYC that disable interaction with WDR5 decrease binding of
MYC to chromatin and attenuate its tumorigenic potential in
mice. These observations led us to speculate that interaction of
MYC with WDR5 stabilizes MYC:MAX dimers on DNA at key
protumorigenic target genes and that as a result the MYC–WDR5
interface could be a focal point for pharmacological inhibition of
MYC. But if the MYC–WDR5 connection is to be therapeutically
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pursued, we need to pinpoint target gene networks that are reg-
ulated by MYC and WDR5 in cancer cells and determine if these
are relevant to the broad tumorigenic functions of MYC. Impor-
tantly, we also need to establish whether disrupting the MYC–
WDR5 interaction in the context of a preexisting cancer will pro-
mote its regression. This latter criteria is of premier importance for
cancer therapy, but is a standard that is rarely met for MYC
cofactors.
Here, we describe a Burkitt’s lymphoma (BL) system that al-
lows us to interrogate transcriptional programs that are controlled
by the MYC–WDR5 connection and to evaluate its importance
for tumor maintenance. We show that WDR5 recruits MYC to
regulate a set of genes that are linked to protein synthesis and
demonstrate that disrupting the MYC–WDR5 interaction is as
effective as disabling all of the DNA-binding capabilities of MYC
at promoting tumor regression. These findings solidify the concept
that, if a therapeutic window can be established, inhibitors of the
MYC–WDR5 connection could have antitumor activity.
Results
An Inducible Exon Swap System to Study the MYC–WDR5 Interaction.
To probe the importance of the MYC–WDR5 interaction in the
context of a MYC-driven cancer, we built a system that allows
exchange of wild-type (WT) for WDR5-interaction-defective
(WBM) MYC in a BL cell line. We chose the Ramos BL line,
because it carries the t(8:14) translocation that places c-MYC un-
der the control of the IgH locus (Fig. 1A), and does not express the
untranslocated c-MYC allele (13). This system enabled us to ex-
press the WBM mutant as the sole form of MYC in the cell and
determine the impact of loss of interaction with WDR5 on pri-
mary transcriptional processes, as well as tumor engraftment and
maintenance.
Fig. 1. Inducible c-MYC exon swap in a BL cell line. (A) Structure of the c-MYC gene in Ramos cells (Top). Chromosome 14 is in red and shows part of the IgH
locus including the constant (Cμ) and switch (Sμ) regions. Chromosome 8 is depicted in blue and shows exons 1 to 3 of c-MYC (Ex1–Ex3). Schematic of the
modified locus in the unswitched state (Middle). Ex3R; recoded WT exon 3. P2A, “self-cleaving” peptide; PURO, puromycin resistance gene; TER, transcrip-
tional terminator; eEx3, exchanged exon 3 (encoding WT, WBM, or Δ264 MYC sequences); HA, hemagglutinin epitope tag. LoxP sites are the black triangles.
Configuration of the altered locus after activation of ER-linked CRE recombinase (Bottom). (B) Cells were treated with 20 nM OHT for 24 h, and GFP-positive
cells scored by flow cytometry. The percentage of GFP-positive cells in each population is shown. (C) Western blot, performed on lysates from parental Ramos
CRE–ER expressing cells (Ram), or modified cells expressing the WT, WBM, or Δ264 c-MYC proteins. Cells were untreated (−) or treated (+) with 20 nM OHT for
24 h prior to lysate preparation. Blots were probed with anti-HA, anti-MYC, anti-WDR5, and anti-GAPDH (GD) antibodies as indicated. (D) Engineered Ramos
cells were switched to express the indicated MYC protein and subject to biochemical fractionation into nuclear and cytosolic extracts. Extracts were then
probed with antibodies against HA (switched MYC), histone H3 (H3; nuclear), or GAPDH (GD; cytosolic). (E) Cell lines were treated with 20 nM OHT (24 h),
lysates prepared, and HA-tagged MYC proteins immunoprecipitated (IP) by an anti-HA antibody. Immune complexes (lanes 1 through 4) were then probed for
WDR5, HCF-1, MAX, or HA-tagged MYC by Western blotting. A sample of the lysates (input) were also probed by Western blot (lanes 5 through 8). This IP is
representative of 3 independent experiments.
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The WBM mutation (I262E/V264E/V265E) alters residues
encoded within the third exon of c-MYC, permitting us to use an
exon 3 swap strategy to express WBM mutant MYC (Fig. 1A).
We also included a WT exon 3 swap as a control, and another
exon 3 swap that truncates MYC at residue 264 (Δ264), removing
sequences required for nuclear localization and DNA binding.
Ramos cells were engineered to express CRE recombinase linked
to the estrogen receptor hormone binding domain (CRE–ER).
We then used CRISPR-facilitated homologous recombination to
introduce these modules into the translocated c-MYC locus (SI
Appendix, Fig. S1A) and identified clones with appropriate in-
tegration by Southern blotting (SI Appendix, Fig. S1 B and C). This
strategy replaces endogenous exon 3 of c-MYC with a LoxP-
flanked cassette that carries a recoded wild-type exon 3 (Ex3R),
a puromycin resistance gene (PURO), and a transcriptional ter-
minator (TER). Activation of CRE–ER in these cells excises the
Ex3R-PURO-TER cassette (Fig. 1A), bringing in place exchanged
exon 3 (eEx3) encoding WT, WBM, or Δ264 MYC sequences.
After swap, MYC proteins carry an HA-epitope tag, and swapped
cells express green fluorescent protein (GFP). We refer to these
lines as “WT,” “WBM,” and “Δ264,” either “unswitched” or
“switched.”
To trigger the switch, we treated cells with 4-hydroxytamoxifen
(OHT) for 24 h, at which time ∼80 to 90% of cells were GFP
positive (Fig. 1B). At that time, and in an OHT-dependent man-
ner, we detected robust expression of all 3 HA-tagged proteins
(Fig. 1C). Probing for total c-MYC levels (Fig. 1C), endogenous
MYC was undetectable after switch and was replaced by the
switched MYC species, which—for the WT and WBM MYC
proteins—were expressed at levels similar to endogenous MYC.
The Δ264 MYC protein is not detected by the α-MYC antibody
we used, but is expressed at higher levels than WT MYC, as de-
termined by α-HA blotting (Fig. 1C). The steady-state WDR5
levels are unaffected by the switch (Fig. 1C), and, as expected (8),
the WBM MYC mutant: 1) localizes to the nuclear fraction (Fig.
1D), 2) retains the ability to associate with MAX and HCF-1 (14)
(Fig. 1E), and 3) is defective for interaction with WDR5 (Fig. 1E).
Also as expected, the Δ264 mutant is mostly localized to the cy-
tosol (Fig. 1D) and is defective for interaction with WDR5, HCF-1,
and MAX (Fig. 1E). We conclude that our system is appropriate
for interrogating the consequences of disrupting the MYC–
WDR5 interaction and for comparing these effects with those
associated with a total loss in the ability of MYC to localize to
the nucleus and bind chromatin (Δ264).
MYC and WDR5 Colocalize on Chromatin at Genes Involved in Protein
Synthesis. We first determined the location of MYC and WDR5
on chromatin in Ramos cells. Using chromatin immunoprecipi-
tation coupled to next-generation sequencing (ChIP-Seq), we
identified ∼22,000 MYC-binding sites (Fig. 2A), which were
enriched in the “E-box” DNA motif (Fig. 2B), divided equally
between transcription start site (TSS) proximal and distal (SI
Appendix, Fig. S2A), and linked to genes connected to the core
functions of MYC, including translation (SI Appendix, Fig. S2B).
For WDR5, we tracked ∼450 binding sites (Fig. 2A)—30% of
which contained an E-box (Fig. 2C), and 94% of which are also
bound by MYC (Fig. 2A). As expected from the extensive overlap
of MYC at WDR5-binding sites, the relevant properties of WDR5
sites and WDR5/MYC sites are similar; they are mostly promoter
proximal (Fig. 2D and SI Appendix, Fig. S2C) and strongly enriched
in genes connected to protein synthesis (Fig. 2E and SI Appendix,
Fig. S2D), including ∼50 subunits of the ribosome, nucleolar
RNAs, and translation initiation factors (Dataset S1). Looking
closely at MYC/WDR5 cobound sites, several interesting features
emerge. First, the ChIP-Seq profiles for the 2 proteins are very
similar (Fig. 2 F and G and SI Appendix, Fig. S3) consistent with a
close relationship between the sites bound by MYC and WDR5 at
these locations. Second, although the relationship at cobound sites
is close, there are many sites where MYC shows robust binding to
chromatin in the absence of WDR5 (SI Appendix, Fig. S3). Third,
E-boxes are strongly represented at cobound sites—60% (247) of
these sites carry a perfect E-box, while 97% (408) carry either a
perfect or an imperfect (CAN1N2TG; where N1 is not C and N2 is
not G) E-box motif. Known and de novo motif analysis revealed
that, compared to MYC-only bound sites, MYC/WDR5 cobound
sites are enriched in an extended E-box element (GTCACGT-
GAC; Fig. 2H). Finally, looking specifically at sites with imperfect
E-boxes, the ChIP-Seq signal for MYC is higher for MYC/
WDR5 cobound than MYC-only sites (Fig. 2I), consistent with the
notion that WDR5 facilitates loading of MYC to chromatin at
locations where its DNA recognition sequence is imperfect. Based
on these data, we conclude that most binding of MYC to chro-
matin in Ramos cells occurs independent of WDR5, but that there
is a cohort of genes—connected to protein synthesis—where MYC
and WDR5 share promoter-proximal binding sites.
WDR5 Recruits MYC to Chromatin at Protein Synthesis Genes. We
next asked whether disrupting the MYC–WDR5 interaction impacts
the binding of WDR5 or MYC to chromatin. First, we switched WT
for WBM MYC and performed ChIP-Seq for WDR5. Here, we
found that exchange of endogenous MYC for the WBM mutant
modestly reduced the intensity of WDR5 ChIP-Seq peaks, but had
no impact on the total number of WDR5 peaks detected or the
location of WDR5 peaks across the genome (SI Appendix, Fig. S4 A
and B). Because the WBMmutant is the sole form of MYC in these
cells, we conclude that association of WDR5 with chromatin occurs
largely independent of its ability to interact with MYC.
Next, we performed ChIP-Seq for HA-tagged MYC in both
the Δ264 and WBM switched cells. The Δ264 MYC mutant
failed to bind chromatin, with no ChIP-Seq peaks detected in these
experiments (Fig. 3A). The WBM MYC, in contrast, displayed a
modest reduction in the intensity of chromatin binding genome-
wide (SI Appendix, Fig. S4 C and D), but the vast majority of
MYC-binding events were preserved (Fig. 3A). Indeed, there are
just 88 sites where MYC binding was significantly perturbed by the
WBM mutation (Fig. 3 B and C). Interestingly, these 88 sites have
fewer perfect E-boxes than the MYC/WDR5 cobound sites where
MYC binding is insensitive to the WBM mutation—and they have
more imperfect E-boxes (SI Appendix, Fig. S4E). Although the
number of loci that are sensitive to the WBM mutation was small,
the sites involved are strongly enriched in 2 important character-
istics: 85% of them are bound by WDR5, and more than half are
connected to protein synthesis (Dataset S2). We validated the
ChIP-Seq results with ChIP-qPCR, probing 6 WDR5-bound loci
and 3 genes where MYC binds, but WDR5 was not detected (Fig.
3D). Here, we observed identical results: the WBM mutation
disrupts binding of MYC to WDR5-bound genes, but has little if
any impact on genes that are not bound by WDR5 (Fig. 3D).
These findings demonstrate that interaction with WDR5 is gen-
erally dispensable for chromatin binding by MYC, but that there is
a rarefied cohort of genes—connected to protein synthesis and
with reduced quality DNA-binding sequences—where WDR5 is
important for MYC to associate with chromatin.
Recently, we discovered a small molecule, C6, that binds tightly
to the “WIN” site of WDR5 (12) and displaces it from chromatin
(15). As an orthologous challenge to the concept that WDR5 is
required for MYC recruitment at select loci, we asked if C6 also
displaces MYC. We treated Ramos cells expressing HA-tagged
WT MYC with C6 and performed ChIP for both WDR5 and
MYC. Here, as we observed in MV4:11 cells (15), a 4-h treatment
of Ramos cells with C6 displaced WDR5 from chromatin at the
6 sampled sites (Fig. 3E). Probing for MYC (Fig. 3F), we de-
termined that C6 treatment disrupted MYC binding to these same
6 loci, but had little effect at sites where MYC binds without
WDR5. Under these conditions, C6 did not alter MYC or WDR5
expression (SI Appendix, Fig. S4F) or the MYC–WDR5 interaction
25262 | www.pnas.org/cgi/doi/10.1073/pnas.1910391116 Thomas et al.
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SI Appendix, Fig. S4G). Notably, the magnitude in reduction of
MYC binding upon WIN site inhibitor treatment was very similar
to that observed with the WBM mutation (Fig. 3D), consistent
with the idea that either evicting WDR5 from chromatin, or dis-
rupting the MYC–WDR5 interaction, is sufficient to attenuate
MYC binding at these loci.
Interaction of MYC with WDR5 Is Important for Protein Synthesis
Gene Transcription. Next, we used precision run on (PRO)-Seq (16)
to monitor the distribution and density of active RNA polymerases
across the genome after switching. To establish a baseline, we first
compared WT with Δ264 switched cells, 24 h after OHT treat-
ment. Compared to the WT switch, switching to the Δ264 mutant
decreased transcription at ∼3,400 genes and increased transcrip-
tion at about 1,200 genes (Fig. 4A and SI Appendix, Fig. S5A).
Although these transcriptional changes were modest, they were
entirely consistent with MYC inactivation: there was a strong
tendency of MYC-bound genes to be transcriptionally altered in
the presence of the Δ264 mutant (SI Appendix, Fig. S5B), and we
observed significant enrichment in gene signatures linked to
MYC, including hallmark MYC gene sets, mTORC1 signaling,
and glycolysis (SI Appendix, Fig. S5C). PRO-Seq can thus capture
a broad range of transcriptional changes associated with loss of
MYC function in this system.
Next, we compared the WT switch to that of the WBM mutant.
Here, transcriptional changes were of the same magnitude as the
Δ264 MYC protein, but affected fewer genes (Fig. 4B and SI Ap-
pendix, Fig. S5A). In total, there were 128 genes where transcription
Fig. 2. MYC andWDR5 colocalize at cohort of protein synthesis genes in Ramos cells. (A) Venn diagram, showing overlap of HA–WT–MYC andWDR5-binding
sites—as determined by ChIP-Seq (false discovery rate [FDR] = 0.01). HA–WT–MYC was monitored in switched WT cells; WDR5 was monitored in unswitched
WBM cells that express endogenous, wild-type, MYC protein. (B) Motif analysis for HA-tagged MYC-binding sites. At Top is known-motif analysis; Bottom is de
novo motif analysis. Significance values and the percentage of ChIP-Seq peaks containing the indicated motif are shown for each. (C) As in B, except for
WDR5-binding sites. (D) Distribution of shared MYC- and WDR5-binding sites, binned according to distance from the nearest annotated TSS. RGA, region–
gene association. (E) The top 8 GO enrichment categories for genes bound by MYC and WDR5 in Ramos cells. (F) Histogram of normalized MYC and WDR5
ChIP-Seq fragment counts at MYC–WDR5 cobound sites in a 1,500-bp window either side of the center of the MYC peaks. (G) IGV screenshot of representative
ChIP-Seq data for HA–WT–MYC and WDR5 in Ramos cells. Shown is the PTGES3 gene, which is bound only by MYC, and NACA, which is bound by both MYC
and WDR5. Blue arrows indicate the position of 2 imperfect E-boxes in the NACA locus. n = 3 independent ChIP-Seq experiments for MYC and WDR5. (H)
Motif analysis for MYC-binding sites at WDR5 cobound genes. At Top is known-motif analysis; Bottom is de novo motif analysis. Other details are as in B. (I)
Histogram of normalized MYC ChIP-Seq fragment counts at sites with imperfect E-boxes that are bound by both MYC and WDR5 (red) or MYC only (blue). A
2,500-bp window either side of the peak center is shown.
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decreased, and 66 genes where it increased, in the presence of
WBM MYC. Although the number of genes showing decreased
transcription in the presence of WBM mutant MYC was small, the
genes themselves are strongly clustered—they are significantly
enriched in those where MYC is displaced from chromatin by the
WBM mutation (Fig. 4C), and as expected contain multiple pro-
tein synthesis genes (Fig. 4D), including ribosome subunits, nu-
cleolar RNAs, and translation factors (Dataset S3). These findings
demonstrate that WDR5 has a functional consequence on MYC-
driven transcriptional events in BL cells and highlight biomass
accumulation as the overwhelming process controlled by the MYC–
WDR5 interaction in this setting.
Interaction with WDR5 Is Essential for Tumor Maintenance by MYC.
The ability of MYC to stimulate protein synthesis has long been
recognized as an important part of its tumorigenic repertoire (1).
The biological clustering of gene expression changes we observe
with the WBM MYC mutant, therefore, predicts that it should
have impaired tumorigenic potential. But how will it compare to
the Δ264 mutant, which globally eliminates chromatin binding by
MYC? To answer this question, we switched WT, Δ264, or WBM
cells in culture, injected these cells into the flanks of nude mice,
and assayed tumor size and mouse survival over time (Fig. 5A).
Consistent with a published report (17), mice receiving WT
switched Ramos cells developed tumors rapidly (Fig. 5B and SI
Appendix, Fig. S6A) and with complete penetrance, and all mice
had to be killed by 19 d after injection (Fig. 5C). In comparison,
both the Δ264 and WBM switched cells displayed delayed tumor
growth (Fig. 5B) and a lag in mouse morbidity (Fig. 5C and SI
Appendix, Fig. S6A). Although mice receiving the Δ264 and WBM
switched cells all eventually developed tumors, these appear to
arise from contaminating unswitched cells in the injected pop-
ulations, as the Δ264 and WBM tumors had much higher levels of
cells with the unswitched exon 3 cassette than WT tumors (Fig.
5D). Based on these data, we conclude that the Δ264 and WBM
forms of MYC are both compromised in their ability to drive tu-
morigenesis in vivo.
Finally, we asked whether switching cells in the context of an
established tumor would impact tumor growth (Fig. 5E). We
injected cells in their unswitched state into the flanks of nude
mice, allowed tumors to grow to ∼200 mm3, and starting at day
15 administered tamoxifen treatment for 3 consecutive days. In
WT MYC cells, switching did not affect the rapid rate of tumor
growth (Fig. 5F and SI Appendix, Fig. S6B), and mouse survival
time was analogous to that observed with preswitched WT cells
(Fig. 5G). In contrast, for both the Δ264 and WBM cells, tumors
regressed rapidly and completely within a week after tamoxifen
treatment (Fig. 5F), and these mice survived the entire 60-d
duration of the experiment (Fig. 5G and SI Appendix, Fig.
S6B). Tumor regression in the Δ264 and WBM cases was ac-
companied by widespread apoptosis, with most of the Δ264 and
WBM tumor cells reporting as Annexin V positive 96 h after
switch induction (Fig. 5H and SI Appendix, Fig. S6 C and D).
Consistent with overlapping phenotypic response of WBM and
Δ264 tumors to switching, RNA-Seq of tumors (SI Appendix, Fig.
S7A) revealed widespread and highly similar gene expression
changes in both cases (SI Appendix, Fig. S7 B and C), with en-
richment in gene expression signatures connected to RAS and
NOTCH signaling, p53, apoptosis, MYC, the cell cycle, and
Fig. 3. Interaction of MYC with protein synthesis genes is WDR5 dependent.
(A) Heatmap, showing HA-tagged MYC peak intensity for each MYC protein
(ChIP-Seq) after switching; the figure displays the combined average of nor-
malized peak intensity (read density) in 100-bp bins ±2 kb around peak cen-
ters. Intensities are ranked based on WT–MYC. (B) As in A, except for the
88 loci where the WBM mutant was associated with a significant reduction in
HA–MYC binding. (C) Two IGV screenshots of normalized representative ChIP-
Seq data for HA-tagged MYC (WT or WBM) in the indicated cell lines after
switching. Both RPL37 and SNROA71C/SNHG17 bind WDR5. n = 3 independent
ChIP-Seq experiments for HA-tagged MYC proteins. (D) ChIP was performed
(anti-HA antibody) in cells switched to the indicated MYC proteins (or parental
Ramos cells). Coprecipitating DNAs were monitored (Q-PCR) with primer sets
spanning ChIP-Seq peaks. Six WDR5-bound loci, and 3 non–WDR5-bound loci,
were probed, as indicated. GB, corresponds to the SNHG15 gene body, where
little MYC is detected. ChIP signal is represented as a percentage of input
DNA. (E) WT engineered Ramos cells were selected after switching to per-
manently express HA-tagged WT MYC. These cells were then treated with
either DMSO or 25 μM C6 for 4 h and WDR5 binding to the indicated loci
probed via ChIP-qPCR. IgG is a negative control ChIP. Primer sets and ab-
breviations are as in D. (F) As in E, except that ChIP-qPCR was performed for
MYC. The mean and SD of 3 experiments are shown.
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mTORC1 (Dataset S4). Importantly, despite the overall simi-
larities in the tumor regression transcriptional profiles, com-
parison of differentially expressed genes between the WBM and
Δ264 tumors demonstrated that genes selectively down-regulated
in the WBM samples were enriched in genes that are decreased
in the WBM mutant for MYC binding (SI Appendix, Fig. S7D)
and for gene expression, as determined by PRO-Seq (SI Ap-
pendix, Fig. S7E). Thus the transcriptional changes we measured
for the WBM mutant in cell culture occurred after switching
in vivo.
Together, these results establish that the ability of MYC to
interact with WDR5 is critical for tumor maintenance in mice.
Moreover, the near identical behavior of the Δ264 and WBM
MYC mutants in both the tumor engraftment and maintenance
assays demonstrates that disrupting the MYC–WDR5 interac-
tions is as effective at promoting tumor regression as disabling all
of the chromatin-binding capabilities of MYC.
Discussion
There is overwhelming evidence that strategies to inhibit MYC
could form the basis of broadly effective anticancer therapies (3,
18). But the absence of well-defined and druggable pockets
within MYC makes the prospect of direct pharmacological inhibition
almost impossible. Here, we present evidence that WDR5—a
small, well-structured, protein with pockets suitable for drug dis-
covery (12)—could be a viable route for MYC inhibition. Within
the context of a canonical MYC-driven cancer, we show that in-
teraction with WDR5 is essential for MYC to bind to and regulate
a set of genes manifestly linked to biomass accumulation and
demonstrate that disrupting the MYC–WDR5 interaction within
an existing cancer promotes widespread apoptosis and tumor
collapse. These findings raise the possibility that the MYC–WDR5
nexus could be an actionable venue for the discovery of new ways
to inhibit MYC.
Mechanistically, our findings provide insights into the MYC–
WDR5 connection. First, because we replace WT for WBM
MYC in the switched cells, and see little impact onWDR5 binding
by CHIP-Seq, we conclude that interaction with MYC does not
serve to recruit WDR5 to chromatin. This finding supports our
earlier contention (8) that recruitment of MYC to chromatin at
select sites depends on recognition of a prebound and proximal
WDR5 protein. What localizes WDR5 to these sites is, however,
unknown. Recruitment of WDR5 is WIN site dependent (15), and
so it is likely that WDR5 is tethered to these locations by engaging
an arginine-containingWIN motif (consensus “ARA”; ref. 12) in a
chromatin-resident protein. Motif analysis revealed that MYC/
WDR5 cobound genes are enriched in an extended E-box con-
sensus (Fig. 2H) that matches the “CLEAR element” present
in lysosomal biogenesis genes (19) where it is bound by the
micropthalmia-transcription factor E (MiT/TFE) subfamily of
basic helix–loop–helix (bHLH) transcription factors (20); whether
members of the MiT/TFE family of transcription factors play a
role in the initial recruitment of WDR5 to these sites awaits fur-
ther investigation. Second, we show that not all sites of MYC/
WDR5 colocalization on chromatin are sites of facilitated re-
cruitment; the WBM mutation reduces binding of MYC to just
88 of the 418 MYC/WDR5-binding sites in Ramos cells (Fig. 4B),
and it is within these 88 “WBM sensitive” genes that we observe
transcriptional decreases by PRO-Seq (Fig. 4C). Importantly, we find
that the 88 WBM sensitive sites differ from other MYC/WDR5
cobound sites in that they have significantly fewer perfect—and
more imperfect—E-box elements. Thus the dependency of MYC
on interaction with WDR5 correlates with the lower quality of
DNA elements in these targets, providing a simple rationale for
the importance of the MYC–WDR5 interaction in stabilizing
MYC on chromatin at these sites.
Identification of protein synthesis as the biological context in
which MYC and WDR5 cooperate is notable, as connections be-
tween the tumorigenic actions of MYC and the protein synthesis
machinery are extensive (1). MYC regulates transcription by all 3
nuclear RNA polymerases (21), and has widespread control of
RNA polymerase II-transcribed genes linked to protein synthesis
Fig. 4. The MYC–WDR5 interaction is important for transcription of genes
connected to protein synthesis. (A) Heatmap, displaying log2-fold change
of active polymerases in Δ264 switched cells (compared to WT switched
cells) in the promoter-proximal region and ±5 kb around the TSS (200-bp
bins), as determined by PRO-Seq. (24 h after switch). The Top of the figure
shows genes where transcription in the GB decreased (GB down); the
Lower part shows genes where gene body transcription increased (GB up).
(B) As in A but for WBM switched cells. (C ) Gene set enrichment analysis
(GSEA) comparing genes with a reduction in MYC binding in WBM mu-
tation determined by ChIP-Seq against a gene list ranked by alteration in
the density of gene body-associated transcribing polymerases in the WBM
mutant vs. WT, as determined by PRO-Seq. (D) The top 8 GO enrichment
categories for genes displaying a decrease in gene body-associated
RNA polymerases in WBM switched cells. Numbers in italics represent
the number of genes in each category. n = 2 independent PRO-Seq
experiments.
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(22). There is growing support for the concept that targeting ri-
bosome biogenesis could be an effective anti-MYC strategy (23)
and an established precedent that a 2-fold reduction in the level of
a single ribosome protein subunit can suppress tumorigenesis by
MYC in vivo (24). Disrupting the interaction of MYC with WDR5
decreases transcription of more than 20 ribosome protein sub-
units, as well as nucleolar RNAs and factors required for
translation initiation. The commonality of enhanced protein syn-
thesis as a tumorigenic MYC mechanism, together with the find-
ing that all 3 MYC family members interact with WDR5 (8, 25),
suggests that strategies to inhibit MYC through WDR5 could be
pursued to treat a range of malignancies.
In the context of a preformed tumor, switching cells to express
the WBM mutant MYC causes widespread induction of apo-
ptosis, associated with rapid tumor loss. This mechanism of tu-
mor regression is similar to what has been described for other
models of MYC inactivation (26–28), and supports the idea that
MYC can be therapeutically targeted through WDR5 to reverse
malignancy. The MYC–WDR5 interface is small and well struc-
tured and should be amenable to pharmacological inhibition (8).
But one of the surprising aspects of this work is the realization that
targeting the MYC–WDR5 interface may not be absolutely re-
quired to inhibit chromatin binding of MYC through WDR5. Our
recent discovery that inhibitors of the WIN site of WDR5—which
is on the opposite side of WDR5 to the MYC interface—displace
Fig. 5. The ability of MYC to interact with WDR5 is required for tumor growth and maintenance. (A) Schematic of tumor formation assay. Unswitched WT,
Δ264, or WBM cells were grown in culture and pulsed 3 times with OHT to induce the switch. Cells were then injected into a flank of nude mice, and tumor
growth was monitored. (B) Average tumor volumes in mice injected with the indicated switched Ramos cells over days 5 to 17 of the experiment. Tumor volumes
for Δ264 and WBM cells were significantly different (*) fromWT (P < 4.84E-3; 2-tailed t test). (C) Kaplan–Meier survival curves of mice injected with switchedWT,
Δ264, orWBM cells (n = 9 per group); P < 0.0001 (log-rank test). (D) PCR assay for presence of unswitched cells in tumor samples taken at time of sacrifice. Each dot
represents a single mouse. The horizontal cross represents the mean for each group. Note that we were unable to extract usable DNA from one of the tumors in
the Δ264 group. (E) Schematic of tumor maintenance assay. Unswitched WT, Δ264, or WBM cells were injected into a flank of nude mice, and tumor growth was
monitored. At day 15, mice received 3 consecutive daily injections of tamoxifen to induce the switch, and tumor development was monitored. (F) Average tumor
volumes in mice injected with the indicated unswitched Ramos cells before and after switching were induced, beginning at day 15 (red arrow “Tam”). After
switch, tumor volumes for Δ264 and WBM cells were significantly different (*) fromWT (P < 7.0E-9; 2-tailed t test). (G) Kaplan–Meier survival curves of mice (in F)
(n = 9 per group); P < 0.0001 (log-rank test). (H) For the indicated cell types, tumors were harvested (n = 4 per group) 48 and 96 h following tamoxifen ad-
ministration. Apoptosis was evaluated in the isolated lymphoma cells by staining for Annexin V positivity (Annexin V+) and analysis by flow cytometry. The extent
of Annexin V positivity in Δ264 and WBM tumor cells was significantly different (*) from WT tumors (P < 1.65E-5; 2-tailed t test).
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WDR5 from chromatin (15), together with evidence here that the
small molecule C6 also displaces MYC, hints that WIN site in-
hibitors could be developed to block MYC. The WIN site of
WDR5 is the subject of intense drug discovery efforts from several
groups (15, 29–33) and a number of distinct chemotypes have
been reported. Ultimately, whether this avenue can be pursued
depends on whether a therapeutic window can be established for
WDR5 inhibitors between normal and cancer cells, which likely
both make use of the MYC–WDR5 interaction to regulate protein
synthesis gene expression. It has, however, been possible to es-
tablish a therapeutic window with a protein-based inhibitor of the
MYC–MAX interaction (34), demonstrating that essential MYC
cofactors can be targeted to selectively kill cancer cells. De-
velopment of potent inhibitors with suitable in vivo pharmacological
properties is needed to definitely address this issue.
Finally, a particularly provocative aspect of this work is our
finding that disrupting the MYC–WDR5 interaction has the
same antitumor effect as eliminating the entire carboxy terminus
of MYC (Δ264)—in terms of the mechanism, extent, and per-
manency of tumor loss we observe. The carboxy terminus of MYC
carries sequences required for nuclear localization (35), and for
interaction with cofactors including WDR5 (8), HCF-1 (14), MIZ-1
(36), and MAX (2); yet from an antitumor perspective, disrupting
the interaction with WDR5 is sufficient to recapitulate loss of all of
these critical processes in this model. The importance of this result
is that it demonstrates that challenges associated with pharmaco-
logical inhibition of the MYC:MAX interaction (18) do not need to
be overcome to discover and implement MYC inhibitors, and that
additional MYC cofactors can serve as a viable focal point for
new drug discovery initiatives. Our understanding of the MYC
interactome has blossomed in recent years (37–40), and if some
of these interactors can be understood at the level of structural and
biological detail now available for WDR5, the prospect of multi-
modal approaches to effectively block MYC in the clinic could
become reality.
Materials and Methods
Reagents. Details on plasmid constructions, Ramos cell engineering and
validation, and antibodies used in this study are provided in SI Appendix,
Materials and Methods.
Immunoprecipitations. For each immunoprecipitation, 12 × 106 cells were
treated for 24 h with OHT to activate CRE–ER and 1.5 h with 25 μM MG132
(VWR). Cell lysates were prepared in Kischkel buffer (50 mM Tris·HCl pH 8.0,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and Complete Protease Inhibitor
mixture [Sigma-Aldrich]), briefly sonicated, and subject to immunoprecipita-
tion overnight with the 12CA5 antibody. Immune complexes were captured
with Protein-G agarose (Cell Signaling Technologies), washed in Kischkel buffer,
and resolved by SDS/PAGE followed by immunoblotting.
Flow Cytometry. Flow cytometry experiments were performed in the Van-
derbilt University (VU) and Thomas Jefferson University Flow Cytometry Shared
Resources on an LSRII flow cytometer and data analyzed with FACSDiva soft-
ware (BD Biosciences). For apoptosis assays, cells were stained with Annexin-V-
PE (1:100, Thermo Fisher BDB556422) and 7-AAD prior to analysis.
Chromatin Immunoprecipitation. Ramos cells were plated at 7.5 × 105 per
milliliter ± 20 nM 4-OHT for 24 h for ChIP using switched MYC alleles. To
displace WDR5 with C6, cells were plated at 8 × 106 per milliliter and treated
with 25 μM C6 (or DMSO) for 4 h. ChIP experiments were performed as
described (8) using 12 × 106 cells per reaction. Decrosslinked DNA was di-
luted to 500 μL with water and 7.5 μL was used for each qPCR reaction with
amplicons centered on ChIP-Seq peaks. Percent input was calculated by
comparison to a 30-fold dilution of decrosslinked chromatin. For ChIP-Seq,
3 replicates of ChIP DNA were converted into Illumina sequencing libraries
using the NEBNext Ultra II DNA Library Prep Kit (New England Biolabs).
Sequencing was performed at the VU VANTAGE Shared Resource on an
Illumina HiSeq 2500 (single-end 75-bp reads, ∼40 M reads per sample). Meth-
ods for bioinformatic analyses are described in SI Appendix, Materials
and Methods.
PRO-Seq. For PRO-Seq analysis, 3 × 107 cells were switched for 24 h prior to
analysis and nuclei prepared according to published protocols (41, 42). Fur-
ther details, including methods for bioinformatic analyses, are provided in SI
Appendix, Materials and Methods.
In Vivo Studies. Methods for tumor engraftment and maintenance assays, as
well as tumor switch quantification and tumor RNA-Sequencing are described
in SI Appendix, Materials and Methods. All studies complied with state and
federal guidelines and were approved by the Institutional Animal Care and
Use Committee at Thomas Jefferson University.
Data Availability. All genomic data have been deposited at GEO (GSE126207).
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